Programmed cell death ligand‐1 (PD‐L1) expressed on the surface of cancer cells binds its receptor PD‐1 on effector T cells, thus attenuating their activity in antitumor immunity; not surprisingly, PD‐L1 is also present on the surface of sEVs. Here, CD274 is linked to cancer.